drugset / Trial / NCT00450944
Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia
Phase 1
Completed
10 enrolled
Albert Einstein College of Medicine
National Cancer Institute (NCI) · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Immunotoxins, such as anti-CD19 and anti-CD22, can find cancer cells that express CD19 and CD22 and kill them without harming normal cells. This may be an effective treatment for B-cell acute lymphoblastic leukemia. PURPOSE: This phase I trial is studying the side effects and best dose of anti-CD19 and anti-CD22 immunotoxins in treating patients with refractory or relapsed B-cell acute lymphoblastic leukemia.
Timeline
- Start
- 2006-02-22
- Primary completion
- 2008-10-27
- Completion
- 2010-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Combotox | Protein / enzyme biologic | — | Intravenous |